液体活检技术在结直肠癌精准医疗中的应用与挑战

doi:10.3969/j.issn.1006-7795.2017.06.001

首都医科大学学报 ›› 2017, Vol. 38 ›› Issue (6): 785-789.doi: 10.3969/j.issn.1006-7795.2017.06.001

液体活检技术在结直肠癌精准医疗中的应用与挑战

杨盈赤, 张忠涛

首都医科大学附属北京友谊医院普外科, 北京 100050

收稿日期:2017-10-16 出版日期:2017-11-21 发布日期:2017-12-16
通讯作者: 张忠涛 E-mail:zhangzht@medmail.com.cn
基金资助:
国家科技支撑计划课题（2015BAI13B），北京市卫生系统高层次卫生技术人才培养计划资助项目（2015-3-005）。

Clinical application and challenge of liquid biopsy in the precision medicine of colorectal cancer

Yang Yingchi, Zhang Zhongtao

Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Received:2017-10-16 Online:2017-11-21 Published:2017-12-16
Supported by:
This study was supported by National Science and Technology Support Program (2015BAI13B), Beijing Municipal Health System High-level Health Technician Training Program (2015-3-005).

摘要/Abstract

摘要： 随着精准医疗在肿瘤临床领域中的广泛开展，对肿瘤分子生物学特性进行实时动态监测的需求越来越高。近年来，液体活检以简便快捷、微创、实时、特异性高和克服时空异质性等特点在肿瘤临床诊断与治疗中发挥着越来越重要的价值。本文围绕液体活检的两种主要技术：循环肿瘤细胞和循环肿瘤DNA检测技术的特点，介绍了其在结直肠癌精准医疗领域的最新研究进展，探讨了面临的挑战和可行的解决方案。

关键词: 液体活检, 结直肠癌, 循环肿瘤细胞, 循环肿瘤DNA

Abstract: With the rapid development of precision medicine in cancer,the demand for dynamic monitoring of tumor molecular characteristic has been increased. In recent years, liquid biopsy is currently playing a more and more important role in diagnosis and treatment of cancer in clinical practice due to its convenience, non-invasiveness, high specificity and overcoming temporal-spatial heterogeneity. This review introduces circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) as the most important technique in liquid biopsy, mainly focusing on their technological feature, especially recent research progress in colorectal cancer. Further, the challenge and possible solution are discussed in the clinic application of liquid biopsy.

Key words: liquid biopsy, colorectal cancer, circulating tumor cells, circulating tumor DNA

中图分类号:

R735.3

杨盈赤, 张忠涛. 液体活检技术在结直肠癌精准医疗中的应用与挑战[J]. 首都医科大学学报, 2017, 38(6): 785-789.

Yang Yingchi, Zhang Zhongtao. Clinical application and challenge of liquid biopsy in the precision medicine of colorectal cancer[J]. Journal of Capital Medical University, 2017, 38(6): 785-789.

参考文献

[1] Ryuk J P, Choi G S, Park J S, et al. Predictive factors and the prognosis of recurrence of colorectal cancer within 2 years after curative resection[J]. Ann Surg Treat Res, 2014, 86(3):143-151.
[2] Ignatiadis M, Lee M, Jeffrey S. Circulating tumor cells and circulating tumor DNA:challenges and opportunities on the path to clinical utility[J]. Clin Cancer Res,2015,21(21):4786-4800.
[3] Lowes L E, Bratman S V, Dittamore R, et al. Circulating tumor cells (CTC) and Cell-free DNA (cfDNA) Work Shop 2016:scientific opportunities and logistics for cancer clinical trial incorporation[J]. Int J Mol Sci,2016,17(9):pii:E1505.
[4] Galatea K, Eleni P, Saad A, et al. Evaluation of isolation methods for circulating tumor cells (CTCs)[J]. Cell Physiol Biochem,2016, 40:411-419.
[5] Dive C, Brady G. Snap shot:circulating tumor cells[J]. Cell, 2017,169(1):176.
[6] Newman A M, Bratman S V, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage[J]. Nat Med,2014, 20(5):548-554.
[7] Wong S C, Chan C M, Mab B, et al. Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients[J]. Clin Cancer Res,2009, 15(3):1005-1012.
[8] Sastre J, Maestro M L, Puente J, et al. Circulating tumor cells in colorectal cancer:correlation with clinical and pathological variables[J]. Ann Oncol, 2008, 19(5):935-938.
[9] Amin M B, Edge S, Greene F, et al. AJCC cancer staging manual[M]. 8th. New York:Springer, 2017.
[10] Galizia G, Gemei M, Orditura M, et al. Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients[J]. J Gastrointest Surg,2013,17(10):1809-1818.
[11] Nesteruk D, Rutkowski A, Fabisiewicz S, et al.Evaluation of prognostic significance of circulating tumor cells detection in rectal cancer patients treated with preoperative radiotherapy:prospectively collected material data[J]. Biomed Res Int, 2014, 2014:712827.
[12] Rahbari N N, Aigner M, Thorlund K, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer[J]. Gastroenterology, 2010, 138(5):1714-1726.
[13] Van Dalum G, Stam G J, Scholten L F, et al. Importance of circulating tumor cells in newly diagnosed colorectal cancer[J]. Int J Oncol,2015, 46(3):1361-1368.
[14] Barbazán J, Muinelo-Romay L, Vieito M, et al. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer[J]. Int J Cancer, 2014, 135(11):2633-2643.
[15] Church T R, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer[J]. Gut,2014, 63(2):317-325.
[16] Arena S, Siravegna G, Mussolin B, et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations[J]. Sci Translat Med, 2016,8(324):314-324.
[17] Diaz L J, Williams R T, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers[J]. Nature,2012,486(7404):537-540.
[18] Lecomte T, Berger A, Zinzindohou F, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis[J]. Int J Cancer,2002, 100(5):542-548.

液体活检技术在结直肠癌精准医疗中的应用与挑战

Clinical application and challenge of liquid biopsy in the precision medicine of colorectal cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 12

编辑推荐

Metrics

本文评价

[1]	李荣雪, 张倩, 邢洁, 孙秀静, 李鹏, 焦月, 张澍田. 超声内镜对早期结直肠癌的诊断价值分析[J]. 首都医科大学学报, 2023, 44(1): 126-130.
[2]	王芸, 李文坤, 苏珈仪, 王亚丹, 吴静. 系统免疫炎症指数在早期结直肠癌及癌前病变筛查中的应用价值[J]. 首都医科大学学报, 2022, 43(5): 760-766.
[3]	司海, 刘然, 熊中原, 曹邦伟. 细胞角蛋白的表达水平与结直肠癌临床病理学特征的相关性研究[J]. 首都医科大学学报, 2022, 43(1): 127-131.
[4]	姚健楠, 高天博, 段凌, 刘健, 蒋玉良, 安广宇, 葛洋. 结直肠癌中O-型糖基化相关差异基因的筛选及分析[J]. 首都医科大学学报, 2020, 41(3): 403-410.
[5]	徐谊, 赵晓牧, 李亚伦, 郭炜, 孙武青, 王今. 128例50岁以下结直肠癌患者的临床特点及预后分析[J]. 首都医科大学学报, 2019, 40(1): 136-142.
[6]	汪栋, 金岚, 姚宏伟, 王今, 赵晓牧, 吴国聪, 杨盈赤, 张忠涛. 35例同时性多原发结直肠癌患者临床诊疗分析[J]. 首都医科大学学报, 2018, 39(3): 413-417.
[7]	田正凤, 陈洪, 翟爱军, 王亚东, 王贵齐, 贺舜. 北京云岗地区体检人群结直肠癌机会性筛查结果分析[J]. 首都医科大学学报, 2016, 37(1): 34-37.
[8]	李艳萍, 李骥, 盖小荣, 吴军, 李文彬, 吴东, 姚方, 李景南. 结直肠息肉发病危险因素分析[J]. 首都医科大学学报, 2013, 34(5): 684-688.
[9]	伍冀湘;梁杰雄;王宇夫;李雅君;温绍君;李进军;邵天松;邱力新;何平. 腹腔镜和开腹结直肠癌根治手术患者外周血中CK20mRNA的表达及意义[J]. 首都医科大学学报, 2007, 28(1): 10-13.
[10]	曹广;李非;孙家邦. 胰腺炎相关蛋白与结直肠癌DNA倍体性的关系[J]. 首都医科大学学报, 2004, 25(2): 243-245.
[11]	田德清;于跃明;单保恩;李春仲;王桂英;安广权;马强. 大肠癌组织端粒酶活性检测[J]. 首都医科大学学报, 2004, 25(1): 95-97.
[12]	张越巍;巢仰云;范东坡. 胆囊切除术和胆囊结石与结直肠癌的关系[J]. 首都医科大学学报, 2000, 21(4): 325-326.